New York, NY -- (SBWIRE) -- 10/25/2018 -- A vaccine is a biological medical product designed to stimulate antibodies inside human body. Vaccine helps in providing immunity against various infectious diseases. Some of the common types of vaccine include inactivated vaccines, subunit vaccines, DNA vaccines and recombinant vector vaccines. Vaccines may be prophylactic and therapeutic. Therapeutic vaccine is a biological combination designed to develop immunity against a diseased cell or tissues. Therapeutic vaccines are developed to treat ailments from various cancers, HIV and Alzheimer's disease. Therapeutic vaccine is used for cure and prevention of cancer whereas prophylactic vaccines are only used for prevention of cancer. Therapeutic vaccines are specially designed for HIV positive people who have healthy immune system. HIV virus damages human immune system, which results into weaker immune system and thus leading to less ability to fight with microorganisms. Therapeutic vaccines spur the immune system to attack targeted tissue. A therapeutic HIV vaccine is also known as treatment vaccines. Some of the drugs used for HIV treatment include atripla, epzicom, prezista, truvada, kaletra, isentress, reyataz and viread. In addition, there are large numbers of therapeutic vaccines which are under clinical developments. Therapeutic vaccines are also used to treat cancer as they provide greater bioavailability and specificity with minimal side effects. Some of the side effects associated with therapeutic vaccines are swelling, redness, soreness and pain at the site of injection. In addition, mild-flu like symptom is another side effect for therapeutic vaccines.

Request Sample Report@ https://www.persistencemarketresearch.com/samples/3705

North America followed by Europe is dominating the global therapeutic vaccines market due to increasing accessibility and affordability of highly expensive tests for HIV and cancer. Rising technological support for the development of new vaccines is also fuelling the growth of the North American therapeutic vaccines market. Asia is expected to be the fastest growing market in coming five years due to rising prevalence of various infectious diseases and aging population.

In recent time there is increased use of therapeutic vaccines due to rising incidence of diseases such as cancer and HIV. Technological advancements in HIV diagnosis and rising number of clinical trials for HIV and cancer vaccines are some of the key factors driving the growth of the global therapeutic vaccines market. In addition, increasing awareness among people for severe diseases and increasing R&D investments for therapeutic vaccines are also fuelling the growth of the therapeutic vaccines market. However, higher cost of vaccines and less availability of therapeutic drugs are some of the key factor restraining the global therapeutic vaccines market. In addition, stringent regulation for the approval of therapeutic vaccines is also inhibiting the global therapeutic vaccines market.

Request TOC@ https://www.persistencemarketresearch.com/methodology/3705

Human papillomavirus mediated malignancies could develop an opportunity for the growth of the global therapeutic vaccines market. Adverse side effects of therapeutic vaccination could lead a challenge for the growth of the global therapeutic vaccines market. Some of the trends for the growth of the global therapeutic vaccines market are rising number of product innovation and rising number of mergers and acquisitions. Some of the major companies operating in the global therapeutic vaccines market are Agenus, Inc., GlaxoSmithKline, Novartis AG, Pfizer, Argos Therapeutic Inc., Merck & Co., Celldex Therapeutic Inc., Cytos Biotechnology AG and Dendreon Corp.